Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Next week presentation at Cantor.

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Mar 30, 2023 9:37am

185 Views

Post# 35368871

RE:Next week presentation at Cantor.

Discussion boards have gone quiet...whether one pumps or bashes. Everyone is in wait mode to see when Coffey & the BOD decide to enlighten us as to wtf is going on, or in fact release news on ph3 registrational trials or AA or wtv. It's exasperating that the SP continues to languish, especially when one thinks back to the plethora of amazing news we received between Oct and Dec. 9th. Blackout? Wtv, the retail investor needs something. Does anyone expect BIG news on or the May 9 AGM, or do we head into June's ASCO with a SP on life support?

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?